Nanogen to Launch POC Test for Congestive Heart Failure Based on SynX Subsidiary Work

Even though SynX was successful at finding biomarkers and developing a few ELISA tests, the company realized about two years ago that it did not have the resources to move the biomarkers through the next steps: product development, clinical development, regulatory approval, and sales and marketing. That s when Nanogen came in. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.